Alignment Healthcare (NASDAQ:ALHC) Issues Earnings Results

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) announced its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.07, Zacks reports. The firm had revenue of $926.93 million during the quarter, compared to analyst estimates of $889.83 million. Alignment Healthcare had a negative net margin of 5.84% and a negative return on equity of 108.69%. Alignment Healthcare's revenue was up 47.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.25) EPS. Alignment Healthcare updated its FY 2025 guidance to EPS and its Q2 2025 guidance to EPS.

Alignment Healthcare Trading Down 7.4 %

NASDAQ ALHC opened at $15.53 on Friday. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 1.82. The company has a market capitalization of $3.07 billion, a price-to-earnings ratio of -20.17 and a beta of 1.32. The stock's 50-day simple moving average is $17.27 and its two-hundred day simple moving average is $14.28. Alignment Healthcare has a twelve month low of $5.62 and a twelve month high of $21.06.

Insider Buying and Selling

In related news, insider Christopher J. Joyce sold 25,000 shares of the stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $16.87, for a total transaction of $421,750.00. Following the completion of the sale, the insider now directly owns 390,022 shares in the company, valued at $6,579,671.14. This represents a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, President Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.72, for a total value of $411,600.00. Following the sale, the president now owns 1,576,097 shares in the company, valued at $21,624,050.84. This represents a 1.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,181,855 shares of company stock worth $35,166,057 in the last quarter. 6.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ALHC has been the topic of several recent analyst reports. William Blair reissued an "outperform" rating on shares of Alignment Healthcare in a research note on Friday, February 28th. UBS Group increased their target price on Alignment Healthcare from $16.00 to $17.00 and gave the company a "neutral" rating in a research note on Friday. Barclays lifted their price target on shares of Alignment Healthcare from $8.00 to $9.00 and gave the company an "underweight" rating in a research note on Friday, February 28th. Piper Sandler upped their price objective on Alignment Healthcare from $14.00 to $21.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Finally, Stephens reiterated an "overweight" rating and set a $17.00 price objective on shares of Alignment Healthcare in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $17.17.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.